In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs. SIGN UP NOW

For in the in-person event, a badge is required to get in — registration will open both mornings right outside our event space.. The venue is located in San Francisco Marriott Marquis, 780 Mission Street, San Francisco, CA 94103; The ballroom name is …

2025年1月13日 · How a new Washington affects biopharma: In conversation with Scott Gottlieb . Investor, policy expert and former FDA Commissioner Scott Gottlieb will share his insights on how the Trump administration’s new priorities will affect the biopharma industry, in what could be a turbulent time of policy and political changes.

2025年1月6日 · San Diego-based Velia Ther­a­peu­tics, which was work­ing on so-called mi­cro­pro­teins, is in the process of wind­ing down about two years af­ter a $55 mil­lion Se­ries …

2025年1月7日 · New data from Google’s longevity play Calico and the neuro-focused biotech Denali Therapeutics showed neither of their ALS medicines improved patients’ disease progression after 24 weeks.

reset password. We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours. email

2024年12月19日 · Endpoints News reviews 2024's biopharma winners & losers: Eli Lilly dominates obesity market, megadeals decline, I&I sector thrives, and FDA's setback in misinformation fight.

2025年1月6日 · The FDA released dozens of new draft and final guidance documents covering everything from how to reliably use AI in drug development to how the FDA determines when a ...

2025年1月2日 · A Blue Cross Blue Shield licensee serving parts of Pennsylvania says it will not cover some therapies granted accelerated approval for at least 18 months after the FDA signs off.